Elsevier

Cell Calcium

Volume 22, Issue 4, October 1997, Pages 299-311
Cell Calcium

Research
Mibefradil (Ro 40m5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones

https://doi.org/10.1016/S0143-4160(97)90068-3Get rights and content

Abstract

The actions of the novel calcium (Ca2+) channel antagonist mibefradil (Ro 40–5967), a selective T-type channel blocker in myocardium, were investigated in embryonic rat spinal motoneurones maintained in culture. Whole-cell currents were recorded with the patch-clamp technique. Motoneurones displayed transient, low-voltage-activated (LVA) and, more sustained, high-voltage-activated (HVA) Ca2+ currents. The LVA currents were small and preferentially blocked by amiloride and low doses of nickel. Most of the HVA Ca2+ current flowed through N-type Ca2+ channels, while L-, and P/Q-type channels represented a smaller fraction. Mibefradil caused a rapid and reversible dose-dependent block of inward Ca2+ channel currents. Inhibition was nearly complete at 10 μM suggesting mibefradil blockade of all subclasses of Ca2+ channels. The IC50 was approximately 1.4 μM on currents measured at 0 mV, from a holding potential of −90 mV. Inhibition of LVA Ca2+ current occurred over the same concentration range. Slow tail currents induced by the dihydropyridine agonist Bay K 8644 were also blocked by mibefradil, although with a slightly lower potency (IC50 = 3.4 μM). These broad inhibitory effects of mibefradil on Ca2+ influx were also supported by the strong inhibition of depolarization-induced intracellular calcium transients, measured from Indo-1 loaded motoneurones imaged with confocal microscopy. We conclude that mibefradil has potent blocking effects on Ca2+ channels in mammalian motoneurones. We hypothesize that therapeutic and pharmacological effects of mibefradil may involve actions on Ca2+ channels other than type T.

References (35)

  • S.K. Mishra et al.

    Selective inhibition of T -type Ca2+ channels by Ro 40–5967

    Circ Res

    (1994)
  • G. Mehrke et al.

    The Ca(++) channel blocker Ro 40–5967 blocks differently T-type and L-type Ca++ channels

    J Pharmacol Exp Ther

    (1994)
  • W. Osterrieder et al.

    In vitro pharmacologic profile of Ro 40–5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action

    J Cardiovasc Pharmacol

    (1989)
  • J.P. Clozel et al.

    Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil

    J Cardiovasc Pharmacol

    (1989)
  • M.C. Portegies et al.

    Lack of negative inotropic effects of the new calcium antagonist Ro 40–5967 in patients with stable angina pectoris

    J Cardiovasc Pharmacol

    (1991)
  • S. Roux et al.

    Mechanism of the anti-ischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine

    J Cardiovasc Pharmacol

    (1996)
  • R. Schmitt et al.

    Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel

    Arterioscler Thromb Vasc Biol

    (1995)
  • Cited by (0)

    View full text